Results 181 to 190 of about 261,210 (338)

Experimental and statistical post-validation of positive example EST sequences carrying peroxisome targeting signals type 1 (PTS1) [PDF]

, 2012
Thomas Lingner, Amr R. A. Kataya, Sigrun Reumann   +2 more
openalex   +1 more source

ARP2/3 complex associates with peroxisomes to participate in pexophagy in plants [PDF]

, 2022
Jan Martínek, Petra Cifrová, Stanislav Vosolsobě, Jana Krtková, Lenka Sikorová, Kateřina Malínská, Zdeňka Mauerová, Ian Leaves, Imogen Sparkes, Kateřina Schwarzerová   +9 more
openalex   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

The Direct Effect of Hepatic Peroxisome Proliferators on Rat Leydig Cell Function in Vitro¹ [PDF]

, 1996
Raymond C. M. Liu, Cindy Hahn, Mark E. Hurtt   +2 more
openalex   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease

, 2007
Randy L. Hunter, Guoying Bing
openalex   +2 more sources

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Chemical synthesis, docking studies and biological effects of a pan peroxisome proliferator-activated receptor agonist and cyclooxygenase inhibitor

, 2013
José Roberto Santin, Flávia De Toni Uchôa, Maria do Carmo Alves de Lima, Marcelo Montenegro Rabello, Isabel Daufenback Machado, Marcelo Zaldini Hernandes, Angélica Amorim Amato, Flora Aparecida Milton, Paul Webb, Francisco de Assis Rocha Neves, Suely Lins Galdino, Ivan Rocha Pitta, Sandra Helena Poliselli Farsky   +12 more
openalex   +1 more source

Regulation of Peroxisome Proliferator–Activated Receptor-γ Activity by Mammalian Target of Rapamycin and Amino Acids in Adipogenesis [PDF]

, 2004
Jae Eun Kim, Jie Chen
openalex   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source